Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes

[21] Offner F(2019)How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia Blood. 133 1298-782

[22] Mayer J(2019)IGH translocations in chronic lymphocytic leukemia: clinicopathologic features and clinical outcomes Am J Hematol 94 338-257

[23] O'Dwyer M(2018)Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre Br J Haematol 183 421-272

[24] Hellmann A(2013)Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients Br J Haematol 162 774-694

[25] Schuh A(2017)Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017 Eur J Cancer 83 247-2126

[26] Siddiqi T(2010)Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest. 137 263-992

[27] Polliack A(2005)Subcommittee on control of anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 692-1151

[28] Tam CS(2015)Subcommittee on Control of A. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH J Thromb Haemost 13 2119-e267

[29] Suri D(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-2307

[30] Cheng M(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-891

[21] Offner F(2019)How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia Blood. 133 1298-782

[22] Mayer J(2019)IGH translocations in chronic lymphocytic leukemia: clinicopathologic features and clinical outcomes Am J Hematol 94 338-257

[23] O'Dwyer M(2018)Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre Br J Haematol 183 421-272

[24] Hellmann A(2013)Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients Br J Haematol 162 774-694

[25] Schuh A(2017)Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017 Eur J Cancer 83 247-2126

[26] Siddiqi T(2010)Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest. 137 263-992

[27] Polliack A(2005)Subcommittee on control of anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 692-1151

[28] Tam CS(2015)Subcommittee on Control of A. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH J Thromb Haemost 13 2119-e267

[29] Suri D(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-2307

[30] Cheng M(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-891